STOCK TITAN

ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. reported results of its 2026 annual meeting of stockholders held via live webcast. Stockholders elected three Class II directors—James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D.—to serve until the 2029 annual meeting.

Of 46,368,442 common shares eligible to vote as of April 21, 2026, 33,418,793 shares, or 72.07%, were present or represented by proxy, satisfying quorum requirements. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares outstanding eligible to vote 46,368,442 shares Common stock eligible as of April 21, 2026 record date
Quorum shares represented 33,418,793 shares (72.07%) Shares present or by proxy at 2026 annual meeting
Votes for James Healy 18,058,285 shares Election of Class II director at 2026 annual meeting
Votes for John Hohneker 28,043,164 shares Election of Class II director at 2026 annual meeting
Votes for Stuart Lutzker 29,495,923 shares Election of Class II director at 2026 annual meeting
Votes for auditor ratification 33,411,773 shares Ratification of PwC as auditor for fiscal year 2026
quorum financial
"a quorum of 33,418,793 shares, or 72.07% of the eligible shares, was present"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"the number of broker non-votes on each of the foregoing matters are set forth below"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Emerging Growth Company regulatory
"Emerging Growth Company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Annual Meeting financial
"held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001868279 0001868279 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 18, 2026

 

ARRIVENT BIOPHARMA, INC. 

(Exact name of registrant as specified in its charter)

 

Delaware   001-41929   86-3336099
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

18 Campus Boulevard, Suite 100

Newtown Square, PA

  19073
(Address of principal executive offices)   (zip code)

 

Registrant’s telephone number, including area code: (628) 277-4836

 

N/A 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   AVBP   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 18, 2026, ArriVent BioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 46,368,442 shares of common stock, par value $0.0001 per share, issued and outstanding and eligible to vote as of the record date of April 21, 2026, a quorum of 33,418,793 shares, or 72.07% of the eligible shares, was present at the meeting or represented by proxy.

 

At the Annual Meeting, the stockholders: (1) elected each of James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D. to the Company’s board of directors as a Class II director for a term of three years to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal (“Election of Directors”); and (2) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Auditor Ratification”). A more complete description of each of these matters is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2026.

 

The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

 

1. Election of Directors

 

Nominee   Shares Voted For  

Shares Voted to Withhold

Authority

  Broker Non-votes
James Healy, M.D., Ph.D.   18,058,285   11,527,650   3,832,858
John Hohneker, M.D.   28,043,164   1,542,771   3,832,858
Stuart Lutzker, M.D., Ph.D.   29,495,923   90,012   3,832,858

 

2. Auditor Ratification

 

Shares Voted For   Shares Voted Against   Shares Abstaining   Broker Non-votes
33,411,773   829   6,191   0

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ARRIVENT BIOPHARMA, INC.
     
  By: /s/ Winston Kung
    Winston Kung
    Chief Financial Officer and Treasurer

 

Date: June 22, 2026

 

 

 

FAQ

What did ArriVent BioPharma stockholders approve at the 2026 annual meeting?

Stockholders elected three Class II directors and ratified PricewaterhouseCoopers LLP as independent auditor for 2026. These actions confirm the company’s proposed board composition and its choice of audit firm for the fiscal year ending December 31, 2026.

How many ArriVent BioPharma shares were eligible to vote at the 2026 meeting?

A total of 46,368,442 shares of common stock were issued, outstanding, and eligible to vote as of the April 21, 2026 record date. This share count determined which stockholders could participate in the 2026 annual meeting voting process.

What quorum was achieved at ArriVent BioPharma’s 2026 annual meeting?

The meeting reached a quorum with 33,418,793 shares present or represented by proxy, equal to 72.07% of eligible shares. Achieving this quorum allowed all director elections and auditor ratification proposals to be validly considered and approved by stockholders.

How did ArriVent BioPharma stockholders vote on the 2026 director nominees?

James Healy received 18,058,285 votes for and 11,527,650 withheld, with 3,832,858 broker non-votes. John Hohneker received 28,043,164 votes for and 1,542,771 withheld. Stuart Lutzker received 29,495,923 votes for and 90,012 withheld, each with 3,832,858 broker non-votes.

What were the vote totals for ratifying ArriVent BioPharma’s independent auditor?

For auditor ratification, 33,411,773 shares voted for PricewaterhouseCoopers LLP, 829 voted against, and 6,191 abstained, with zero broker non-votes. This strong approval confirms PwC as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Filing Exhibits & Attachments

3 documents